In DepthInfectious Disease

Ebola vaccines racing forward at record pace

See allHide authors and affiliations

Science  12 Sep 2014:
Vol. 345, Issue 6202, pp. 1228-1229
DOI: 10.1126/science.345.6202.1228

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Experimental Ebola vaccines started human tests last week and beginning in November may be rolled out to as many as 10,000 people in West Africa. The two vaccines being tested first must prove safe and capable of stimulating relevant immune responses in small trials taking place in four countries. No vaccine has ever moved more quickly into widespread use. Many issues remain on how to determine whether the vaccines actually protect people from Ebola. Because the vaccines are in short supply, they also will only be offered to health care workers and other first-line responders. One vaccine is being manufactured by a collaboration between the U.S. National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, and the other is being made by NewLink Genetics.